Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, and Rosebraugh C
The Bigger Picture: Rethinking Addiction at the Molecular Level What makes the GLP-1 story so significant is what it reveals about addiction itself
Diabetes care 27 (8), 18791884
A dual-action GLP-1/GIP receptor agonist that has shown even greater weight loss results than semaglutide in head-to-head trials up to 22.5% body weight reduction
For semaglutide, this means 0.25 mg weekly for the first four weeks
Still, knowing what is common, what is temporary, and what may be dangerous can help you stay safer and more comfortable during treatment